MedTrace Logo

Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris

NCT01320774 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 588

Last updated 2012-02-10

No results posted yet for this study

Summary

The purpose of this observational study is to evaluate the efficacy, tolerability, quality of life and handling of Daivobet® Gel by both physician and patient in daily practise.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Daivobet® Gel

Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.

Sponsors & Collaborators

  • LEO Pharma GmbH, Neu-Isenburg, Germany

    collaborator UNKNOWN

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Michael Sticherling, Prof dr med · University clinic Erlangen-Nuernberg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01320774 on ClinicalTrials.gov